<DOC>
	<DOCNO>NCT00962533</DOCNO>
	<brief_summary>The purpose trial prove strategy treatment adjustment W24 accord virological response base ROADMAP concept well standard care strategy .</brief_summary>
	<brief_title>EFFicacy Optimization Research Telbivudine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male female , 18 ( inclusive ) 65 ( inclusive ) year age HBsAg HBeAg positive six month Patient willing able comply study drug regimen study requirement Patients must give write informed consent assessment perform Detected M204I/V , N236T , A181V/T mutation patient serum HBV DNA Screening visit Patient history clinical signs/symptoms hepatic decompensation Patient history hepatocellular carcinoma ( HCC ) finding suggestive possible HCC Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>